Hello everyone,
Mark it, we are 5 for 5 in 2023 with over 340% in bookable gains. However, that does not count potential additional bookable gains in GROM which is up 45% today blowing past $2.50/share in after hours trading as I write this. See our January 10th, 2023 coverage of GROM here.
We reported on NUWE at 10:30 AM EST Monday and caught the low of the day as the stock had stalled around 91k shares traded at $7.60/share. Following our alert NUWE traded as high as $8.35/share blowing past the average daily volume with 454K shares traded and closing at $7.87/share. Over 9% in bookable gains on day one. I believe this one is just getting started. Here’s why…
The latest Fintel numbers show a sizable short position of the tiny 500K float.
Short Interest shares – source: NASDAQ
Short Interest Ratio 0.16 Days to Cover
Short Interest % Float 14.69% – source: NASDAQ (short interest), Capital IQ (float)
Off-Exchange Short Volume 66,476 shares – source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 49.26% – source: FINRA (inc. Dark Pool volume)
Nuwellis, Inc. (NUWE) recently announced some very good preliminary revenue results.
“Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods last year. The fourth quarter growth rate reflects benefits from the Company’s commercial team expansion and focused sales strategy, as well as continued market traction in line with the Company’s penetration of market segments beyond heart failure patients. The fourth quarter revenue by segment was led by Pediatrics, followed by Heart Failure and Critical Care, which increased approximately 92%, 47%, and 24% over the same period last year, respectively.
“Preliminary 2022 revenue growth of approximately 42% for the fourth quarter and 8% for the full year demonstrates continued meaningful progress on the execution of our key strategic initiatives, as the expansion of our field sales team and clinical education specialists, bolstered by our market penetration initiatives and growing body of clinical evidence, drove strong sales momentum in the fourth quarter. We are committed to making the Aquadex SmartFlow® system the standard of care for patients with fluid overload who are not responsive to diuretics, driving strong growth in 2023 and beyond,” said Nestor Jaramillo, President and CEO of Nuwellis.”
Recent News
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex
Chart
NUWE had it’s third test of the 20 DMA today and we believe it could have a sustained break above it soon.
Analyst Targets and Ratings, Source – Market Beat
Revenue Growth
Note* the chart below does not include the preliminary 2022 revenue of $8.5M
Stay tuned for updates on these and some of our other 2023 profiled companies.
The Traders News Team
original NUWE alert below
Nuwellis, Inc. (NASDAQ: NUWE) has been on our watch-list and is starting to move now. We wanted to get this out as soon as possible. Full report to follow.
Less than 500K shares in the float.
Source: Finviz
Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), is a medical technology company focused on transforming the lives of people with fluid overload.
Recent Announced Preliminary Fourth Quarter and Full Year 2022 Revenue Results
The Traders News Team |